Patents by Inventor Liang-Chang Dong
Liang-Chang Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911513Abstract: Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.Type: GrantFiled: November 23, 2020Date of Patent: February 27, 2024Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang Dong, Xishan Chen, Jingmin Shi, Danyong Zhang, Gang Wu
-
Publication number: 20230310401Abstract: Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, an amphiphilic polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and a hydrophilic polymer of polyoxyethylene-polyoxypropylene glycol block copolymer. The mass percentage of the active pharmaceutical ingredient in the pharmaceutical composition is 5 wt % to 60 wt %; the mass percentage of the amphiphilic polymer in the pharmaceutical composition is 3 wt % to 40 wt %; and the mass percentage of the hydrophilic polymer in the pharmaceutical composition is 10 wt % to 90 wt %. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects.Type: ApplicationFiled: June 9, 2023Publication date: October 5, 2023Inventors: Liang Chang DONG, Shizhong ZHANG, Yan JIAO, Danyong ZHANG, Wenfang ZHAO, Jingmin SHI
-
Patent number: 11771690Abstract: A solid particle, a preparation method therefor, and a pharmaceutical composition. The solid particle comprises a porous solid particle and a non-aqueous liquid formula. The non-aqueous liquid formula comprises 0.10-4.00 wt % of a hydrophobic active pharmaceutical agent, 28.00-99.90 wt % of a hydrophobic solubilizing solution, 0-70.00 wt % of a non-ionic surfactant, and 0-1.00 wt % of an antioxidant. The hydrophobic solubilizing solution comprises a medium-chain monoglyceride and diglyceride, and/or a propylene glycol fatty acid monoester.Type: GrantFiled: November 27, 2018Date of Patent: October 3, 2023Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang Dong, Wenbo Ma, Lin Wang
-
Patent number: 11759417Abstract: Disclosed are a pharmaceutical composition, an osmotic pump controlled-release drug delivery system comprising the pharmaceutical composition and a preparation method therefor. The pharmaceutical composition comprises a tablet core and a coating film. The tablet core comprises a drug-pulling layer, and the coating film comprises 50-90 wt % of cellulose acetate and 10-50 wt % of Copovidone. The Copovidone can be obtained by means of the polymerization of vinyl pyrrolidone and vinyl acetate in a molar ratio of 40:60-80:20.Type: GrantFiled: February 28, 2019Date of Patent: September 19, 2023Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang Dong, Xishan Chen
-
Patent number: 11707455Abstract: Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, and a amphiphilic polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The mass ratio of the two is 1:0.23 to 1:3. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects.Type: GrantFiled: November 27, 2018Date of Patent: July 25, 2023Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang Dong, Shizhong Zhang, Yan Jiao, Danyong Zhang, Wenfang Zhao, Jingmin Shi
-
Publication number: 20220257471Abstract: A drug accommodating device of a solid oral formulation and an oral administration and delivery apparatus comprising same. The drug accommodating device comprises a filtering component and a supporting component; the filtering component and the supporting component cooperate with each other to form a space used for bearing drug particles or multiple pills; the filtering component has one or more pore channels allowing a liquid to pass; the pore channels are distributed in the filtering component in an up-down intricate intersection mode; alternatively, a water-soluble polymer material layer is provided on the filtering component.Type: ApplicationFiled: March 12, 2020Publication date: August 18, 2022Inventors: Liang Chang DONG, Yang LEI, Gang WU, Shizhong ZHANG, Jingmin SHI, Xishan CHEN
-
Publication number: 20220110832Abstract: Disclosed is an oral drug delivery device, comprising a tubular member, a drug holding part, a device cap and a turbulence-creating means. The tubular member has openings at both ends and an inner cavity; the opening at one end is a first opening and the opening at the other end is a second opening; the inner cavity communicates the first opening and the second opening. The turbulence-creating means comprises a step structure or a fold structure, and is disposed in the inner cavity and positioned between the second opening and the drug holding part. By using the oral drug delivery device of the present invention, turbulence can be generated during a normal sipping process, thereby providing ample mixing of drug-containing granules or multi-particulates with drinkable liquids. Moreover, the device is telescopic, which reduces the size and is convenient to carry.Type: ApplicationFiled: January 22, 2020Publication date: April 14, 2022Applicant: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang DONG, Yang LEI, Gang WU, Yan JIAO, Jingmin SHI
-
Publication number: 20210369695Abstract: Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, and an polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The mass ratio of the two is 1:0.23 to 1:3. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects.Type: ApplicationFiled: November 27, 2018Publication date: December 2, 2021Applicant: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang DONG, Shizhong ZHANG, Yan JIAO, Danyong ZHANG, Wenfang ZHAO, Jingmin SHI
-
Publication number: 20210169811Abstract: Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.Type: ApplicationFiled: November 23, 2020Publication date: June 10, 2021Applicant: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang DONG, Xishan CHEN, Jingmin SHI, Danyong ZHANG, Gang WU
-
Publication number: 20210015737Abstract: Disclosed are a pharmaceutical composition, an osmotic pump controlled-release drug delivery system comprising the pharmaceutical composition and a preparation method therefor. The pharmaceutical composition comprises a tablet core and a coating film. The tablet core comprises a drug-pulling layer, and the coating film comprises 50-90 wt % of cellulose acetate and 10-50 wt % of Copovidone. The Copovidone can be obtained by means of the polymerization of vinyl pyrrolidone and vinyl acetate in a molar ratio of 40:60-80:20.Type: ApplicationFiled: February 28, 2019Publication date: January 21, 2021Applicant: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang DONG, Xishan CHEN
-
Publication number: 20200368221Abstract: A solid particle, a preparation method therefor, and a pharmaceutical composition. The solid particle comprises a porous solid particle and a non-aqueous liquid formula. The non-aqueous liquid formula comprises 0.10-4.00 wt % of a hydrophobic active pharmaceutical agent, 28.00-99.90 wt % of a hydrophobic solubilizing solution, 0-70.00 wt % of a non-ionic surfactant, and 0-1.00 wt % of an antioxidant. The hydrophobic solubilizing solution comprises a medium-chain monoglyceride and diglyceride, and/or a propylene glycol fatty acid monoester.Type: ApplicationFiled: November 27, 2018Publication date: November 26, 2020Applicant: SHANGHAI WD PHARMACEUTICAL CO., LTDInventors: Liang Chang DONG, Wenbo MA, Lin WANG
-
Patent number: 8343978Abstract: The present invention provides orodispersable tablets and methods of using the same. The tablets and methods are useful, for example, for reducing first pass metabolism of orally administered active agents, enhancing bioavailability of active agents, and/or reducing the time it takes for an active agent to achieve maximal effect in a subject. The tablets, when taken orally, disintegrate or dissolve rapidly such that active agent included in the tablets is absorbed in the buccal cavity. The invention further provides methods of manufacturing any of the tablets disclosed herein and containers that include any of the tablets disclosed herein.Type: GrantFiled: December 16, 2008Date of Patent: January 1, 2013Assignee: Adds Pharmaceuticals LLCInventor: Liang Chang Dong
-
Patent number: 7803401Abstract: A sustained release dosage form includes a capsule made of a thermoplastic polymer having a softening point below 200° C. and an orifice formed or formable within the capsule, an emulsion formulation contained within the capsule, and an expandable composition within the capsule remote from the orifice. The emulsion formulation comprises a drug, an emulsifying surfactant, and an oil. The expandable composition is configured to expand and expel the emulsion formulation through the orifice.Type: GrantFiled: October 30, 2006Date of Patent: September 28, 2010Assignee: Encinal Pharmaceutical Investments, LLCInventors: Liang-Chang Dong, Steven Espinal, Patrick S. L. Wong
-
Publication number: 20100158997Abstract: A thin-walled capsule of defined permeability is produced by blow-molding an aqueous-based polymer composition.Type: ApplicationFiled: December 16, 2009Publication date: June 24, 2010Inventor: Liang Chang DONG
-
Publication number: 20100159002Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.Type: ApplicationFiled: March 2, 2010Publication date: June 24, 2010Inventors: Liang-Chang Dong, Patrick S.L. Wong, Vincent Joseph Ferrari, Steven Espinal
-
Publication number: 20100104638Abstract: An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol.Type: ApplicationFiled: October 23, 2009Publication date: April 29, 2010Inventors: WEI-GUO DAI, LIANG-CHANG DONG, TAE-HONG CHOI, SUNG JOO HWANG, JAE HYUN KIM, DONG HO LEE
-
Publication number: 20100029691Abstract: The present invention provides orodispersable tablets and methods of using the same. The tablets and methods are useful, for example, for reducing first pass metabolism of orally administered active agents, enhancing bioavailability of active agents, and/or reducing the time it takes for an active agent to achieve maximal effect in a subject. The tablets, when taken orally, disintegrate or dissolve rapidly such that active agent included in the tablets is absorbed in the buccal cavity. The invention further provides methods of manufacturing any of the tablets disclosed herein and containers that include any of the tablets disclosed herein.Type: ApplicationFiled: December 16, 2008Publication date: February 4, 2010Applicant: Advanced Drug Delivery Systems Pharmaceuticals, LLCInventor: Liang Chang Dong
-
Publication number: 20090130204Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.Type: ApplicationFiled: January 23, 2009Publication date: May 21, 2009Applicant: ENCINAL PHARMACEUTICAL INVESTMENT INC.Inventors: Liang-Chang Dong, Patrick S.L. Wong, Vincent Joseph Ferrari, Steven Espinal
-
Publication number: 20080181944Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.Type: ApplicationFiled: April 2, 2008Publication date: July 31, 2008Applicant: ALZA CORPORATIONInventors: Liang-Chang Dong, Patrick S.L. Wong, Vincent Joseph Ferrari, Steven Espinal
-
Patent number: 7338663Abstract: The present invention includes an expandable osmotic layer and a coating suspension for providing an expandable osmotic layer, both of which are useful for the manufacture of controlled release dosage forms. The expandable osmotic layer of the present invention may be produced using the coating suspension of the present invention. Advantageously, the coating suspension of the present invention can be used to coat expandable osmotic layers under both wet and dry process conditions without sacrificing the quality of the expandable osmotic layers produced, and therefore provides a relatively robust coating suspension that facilitates commercial production of controlled release dosage forms including a coated expandable osmotic layer.Type: GrantFiled: June 28, 2003Date of Patent: March 4, 2008Assignee: ALZA CorporationInventors: Shaoling Li, Liang-Chang Dong, Padmaja Shivanand, Patrick S. L. Wong